CXCL1, also known as GROα, is an ELR+ CXC chemokine that is structurally and functionally related to CXCL2 (GRO2), CXCL3 (GRO3), and CXCL8 (IL-8). CXCL1, CXCL3, and IL-8 bind to the CXCR2 receptor (CD182) with CXCL1 (GROα) having the highest affinity. CXCL1 has pleiotropic effects on cell proliferation, tumor angiogenesis, invasion, and metastasis and is crucial for the recruitment of neutrophils to inflammatory sites. CXCL1 is frequently overexpressed in many cancers, such as breast cancer, ovarian cancer, colorectal cancer, prostate cancer, and squamous cell carcinoma. Thrombin enhances the secretion of CXCL1 from tumor cells, and these two molecules together induce vascular regulatory proteins and growth factors involved in angiogenesis; this parallels the activity of VEGF, Ang-2, CD31, KDR, CXCR2, MMP1, and MMP2 in HUVEC cells. In addition, PGE2 stimulates expression of CXCL1 in human colorectal carcinoma (CRC) cells through activation of an EGFR-MAPK. CXCL1 (secreted by CRC cells) induces endothelial cell migration and tube formation and is induced by inflammatory cytokines such as IL-1 and TNF. In addition, IL-17A enhances expression of CXCL1 by prolonging the half-life of its constitutively unstable mRNA.

PRODUCT DETAILS

Clone: A19037I

Antibody Type: Monoclonal

Reactivity: Human

Format: CXCL1

Host: Mouse

Isotype: IgG2b, κ

Applications: ICFC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.